You are here: Industry Insights > Biogen

News List

Biogen and Sage Therapeutics to co-develop depression and tremor therapies pharmaceutical-technology
December 01, 2020
Biogen and Sage Therapeutics have entered a global collaboration and licence agreement to jointly develop and commercialise depression and tremor therapies, zuranolone (SAGE-217) and SAGE-324, respectively.
FDA to review Samsung Bioepis and Biogen’s biosimilar SB11 pharmaceutical-technology
November 20, 2020
The US Food and Drug Administration (FDA) has accepted Samsung Bioepis and Biogen’s biologics licence application to review the use of SB11 as a biosimilar referencing Lucentis (ranibizumab).
Financial Report: Biogen contractpharma
October 28, 2020
Commetns: Multiple sclerosis revenues, including $272 million in royalties on sales of OCREVUS, decreased 4%. Total Interferon sales (AVONEX and PLEGRIDY) were down 11% to $474 million.
Scribe Therapeutics, Biogen collaborate to develop CRISPR-based genetic medicines pharmaceutical-business-review
October 10, 2020
Molecular engineering company Scribe Therapeutics has entered into a research collaboration with Biogen for the development of CRISPR-based genetic medicines for neurological diseases.
EMA accepts filing for Biogen/Samsung Bioepis’ Lucentis biosimilar pharmatimes
October 10, 2020
The European Medicines Agency (EMA) has accepted for review the marketing authorisation for Biogen and Samsung Bioepis’ biosimilar referencing Genentech's Lucentis (ranibizumab).
Mylan announces launch of generic version of Biogen’s Tecfidera expresspharma
August 20, 2020
Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS).
Biogen and Denali sign Parkinson’s drug deal worth $2bn pharmaceutical-technology
August 10, 2020
Biogen has entered a binding agreement with Denali Therapeutics to jointly develop and commercialise therapeutics for Parkinson’s disease.
Biogen to study Spinraza in combination with $2-mn Novartis drug expresspharma
July 22, 2020
The one-a-day oral drug is viewed as a potential a rival to Spinraza, which is administered every four months via spinal infusion.
Biogen Submits BLA for Aducanumab in Alzheimer's Disease contractpharma
July 10, 2020
If approved, aducanumab would become the first therapy to reduce the clinical decline of Alzheimer's disease.
Mylan Wins District Court Decision against Biogen's Tecfidera Patent americanpharmaceuticalreview
June 30, 2020
Mylan announced the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera? patent, U.S. Patent No. 8,399,514, for lack of written description.